Varlilumab

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates
Name
Varlilumab
Accession Number
DB11930
Type
Biotech
Groups
Investigational
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Description

Varlilumab has been used in trials studying the treatment of MELANOMA, Skin Ulcer, Burkett's Lymphoma, Mantle cell lymphoma, and Any T-cell Malignancy, among others.

Protein chemical formula
Not Available
Protein average weight
Not Available
Sequences
Not Available
Synonyms
Not Available
External IDs
CDX-1127
Categories
UNII
0125DUV5XC
CAS number
1393344-72-3

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AbciximabThe risk or severity of adverse effects can be increased when Abciximab is combined with Varlilumab.
AbituzumabThe risk or severity of adverse effects can be increased when Varlilumab is combined with Abituzumab.
AbrilumabThe risk or severity of adverse effects can be increased when Varlilumab is combined with Abrilumab.
AdalimumabThe risk or severity of adverse effects can be increased when Adalimumab is combined with Varlilumab.
AdecatumumabThe risk or severity of adverse effects can be increased when Adecatumumab is combined with Varlilumab.
AducanumabThe risk or severity of adverse effects can be increased when Varlilumab is combined with Aducanumab.
AfelimomabThe risk or severity of adverse effects can be increased when Afelimomab is combined with Varlilumab.
AlemtuzumabThe risk or severity of adverse effects can be increased when Alemtuzumab is combined with Varlilumab.
AlirocumabThe risk or severity of adverse effects can be increased when Alirocumab is combined with Varlilumab.
AmatuximabThe risk or severity of adverse effects can be increased when Varlilumab is combined with Amatuximab.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Substance
347911259
Wikipedia
Varlilumab

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedTreatmentAdvanced Breast Carcinoma / Advanced Ovarian Carcinoma1
1CompletedTreatmentAny T-cell Malignancy / Burkett's Lymphoma / CD27 Expressing B-cell Malignancies for Example Hodgkin's Lymphoma / CD27 Expressing B-cell Malignancies, (for Example: Hodgkin's Lymphoma / Chronic Lymphocytic Leukaemia (CLL) / Chronic Lymphocytic Leukemia, Burkett's Lymphoma / Colorectal Adenocarcinoma, Non-small Cell Lung Cancer) / Hormone-refractory Prostate Adenocarcinoma, Ovarian Cancer / Mantle Cell Lymphoma (MCL) / Mantle Cell Lymphoma, Primary Lymphoma of the Central Nervous System / Marginal Zone B Cell Lymphoma) / Primary Lymphoma of the Central Nervous System / Solid Tumors (Metastatic Melanoma, Renal (Clear) Cell Carcinoma1
1RecruitingTreatmentAstrocytoma, Grade II / Glioma, Astrocytic / Gliomas / Malignant Gliomas / Oligoastrocytoma, Mixed / Oligodendrogliomas1
1RecruitingTreatmentMetastatic Lung Non-Small Cell Carcinoma / Refractory Lung Non-Small Cell Carcinoma / Stage III Lung Cancer AJCC v8 / Stage IIIA Lung Cancer AJCC v8 / Stage IIIB Lung Cancer AJCC v8 / Stage IIIC Lung Cancer AJCC v8 / Stage IV Lung Cancer AJCC v8 / Unresectable Lung Non-Small Cell Carcinoma1
1TerminatedTreatmentBladder Cancers / Clear-cell Metastatic Renal Cell Carcinoma / Genitourinary tract neoplasm / Head and Neck Carcinoma / Kidney Diseases / Lung Cancer Non-Small Cell Cancer (NSCLC) / Melanoma / Neoplasms / Neoplasms by Histologic Type / Neoplasms, Kidney / Renal Cell Adenocarcinoma / Triple Negative Breast Cancer (TNBC) / Urologic Diseases / Urologic Neoplasms1
1TerminatedTreatmentClear-cell Metastatic Renal Cell Carcinoma / Genitourinary tract neoplasm / Kidney Diseases / Neoplasms / Neoplasms by Histologic Type / Neoplasms, Kidney / Renal Cell Adenocarcinoma / Urologic Diseases / Urologic Neoplasms1
1TerminatedTreatmentProstate Cancer / Prostatic Neoplasms1
1, 2CompletedTreatmentColorectal Cancer (CRC) / Colorectal Cancer (CRC)-Enrollment Completed / Glioblastoma (GBM) (Phase ll Only) / Glioblastoma (GBM) (Phase ll Only)-Enrollment Completed / Lung Cancer Non-Small Cell Cancer (NSCLC) / Malignant Melanoma of Head and Neck / Malignant Neoplasm of Colon / Melanoma / Ovarian Carcinoma / Ovarian Carcinoma-Enrollment Completed / Renal Cell Carcinoma (RCC) (Phase ll Only) / Squamous Cell Carcinoma of the Head and Neck (SCCHN)1
1, 2RecruitingTreatmentLymphoma, B Cell1
1, 2RecruitingTreatmentMelanoma1
1, 2TerminatedTreatmentUnresectable Stage III or Stage IV Melanoma1
2RecruitingTreatmentActivated B-Cell-Like Diffuse Large B-Cell Lymphoma / ALK-Positive Large B-Cell Lymphoma / Atypical Burkitt/Burkitt-Like Lymphoma / Burkitt-Like Lymphoma With 11q Aberration / Diffuse Large B-Cell Lymphoma Activated B-Cell Type / Diffuse Large B-Cell Lymphoma Associated With Chronic Inflammation / Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type / Diffuse Large B-Cell Lymphoma, Not Otherwise Specified / EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified / EBV-Positive Mucocutaneous Ulcer / Epstein-Barr Virus Positive Diffuse Large B-Cell Lymphoma of the Elderly / Epstein-Barr Virus-Positive Mucocutaneous Ulcer / Epstein-Barr Virus-Positive Neoplastic Cells Present / Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma / High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements / High Grade B-Cell Lymphoma, Not Otherwise Specified / High-Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements / High-Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements / Human Herpes Virus 8-Related Malignant Neoplasm / Human Herpesvirus 8-Positive Neoplastic Cells Present / Human Herpesvirus-8-Positive Neoplastic Cells Present / Intravascular Large B-Cell Lymphoma / Large B-Cell Lymphoma With IRF4 Rearrangement / MYC-Negative B-Cell Lymphoma With 11q Aberration Resembling Burkitt Lymphoma / Plasmablastic Lymphoma / Primary Cutaneous Diffuse Large B-Cell Lymphoma / Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type / Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System / Primary Effusion Lymphomas / Recurrent Adult Burkitt Lymphoma / Recurrent B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma / Recurrent B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classical Hodgkin Lymphoma / Recurrent B-Cell Non-Hodgkin Lymphoma / Recurrent Burkitt Lymphoma / Recurrent Diffuse Large B-Cell Lymphoma / Recurrent Lymphomatoid Granulomatosis / Recurrent Mediastinal (Thymic) Large B-Cell Cell Lymphoma / Recurrent Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma / Refractory B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma / Refractory B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classical Hodgkin Lymphoma / Refractory B-Cell Non-Hodgkin Lymphoma / Refractory Burkitt Lymphoma / Refractory Diffuse Large B Cell Lymphoma / Refractory Mediastinal (Thymic) Large B-Cell Cell Lymphoma / Refractory Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma / Skin Ulcer / Small Intestinal B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Burkitt Lymphoma / Small Intestinal High Grade B-Cell Lymphoma, Not Otherwise Specified / T-Cell/Histiocyte-Rich Large B-Cell Lymphoma1
2SuspendedTreatmentGlioblastomas1
2TerminatedTreatmentMelanoma1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Taxonomy

Description
Not Available
Kingdom
Organic Compounds
Super Class
Organic Acids
Class
Carboxylic Acids and Derivatives
Sub Class
Amino Acids, Peptides, and Analogues
Direct Parent
Peptides
Alternative Parents
Not Available
Substituents
Not Available
Molecular Framework
Not Available
External Descriptors
Not Available

Drug created on October 20, 2016 15:01 / Updated on December 02, 2019 09:14